NASDAQ$NKTR

Nektar Therapeutics · Q1 2020 earnings

Q1 2020 earnings · · Investor relations

Briefing

Reported financial results for the first quarter ended March 31, 2020.

Nektar Therapeutics reported Q1 2020 financial results, with revenue increasing to $50.6 million compared to $28.2 million in Q1 2019, primarily due to a milestone payment from Bristol-Myers Squibb. The net loss for the quarter was $138.7 million, or $0.78 per share, compared to a net loss of $119.6 million, or $0.69 per share, in Q1 2019. The company's cash and investments in marketable securities were approximately $1.5 billion as of March 31, 2020.

  • Revenue increased to $50.6 million, up from $28.2 million in the first quarter of 2019.
  • A $25.0 million milestone payment from Bristol-Myers Squibb contributed to the revenue increase.
  • Net loss was $138.7 million, or $0.78 per share, compared to a net loss of $119.6 million, or $0.69 per share, in the first quarter of 2019.
  • Cash and investments in marketable securities were approximately $1.5 billion as of March 31, 2020.

Headline financials

Total Revenue

$50.6M

Previous: $28.2M+79.2%
EPS (adj)

-$0.53

Previous: -$0.68+22.1%
Capital Expenditures

-$900K

Previous: -$5.65M+84.1%
Free Cash Flow

-$140M

Previous: -$124M-12.4%
Net Income

-$139M

Previous: -$119M-17.0%
Operating Income

-$134M

Previous: -$121M-10.7%
Gross Profit

$46.8M

Previous: $22.8M+105.3%
Cash & Equivalents

$227M

Previous: $107M+112.7%
Total Assets

$1.89B

Previous: $2.17B-12.9%

Revenue & EPS history

Nektar · Revenue · Quarterly

$50.6M

Q1 2020+79.2%vs Q1 2019
Beat estimate in 6 of 16 quarters(38%)
ActualEstimate

Forward guidance

Nektar expects enrollment and study starts managed by partners will likely be delayed from three to six months due to COVID-19 but the company's strong financial position provides a solid foundation.

Headwinds

  • Enrollment and study starts managed by partners will likely be delayed from three to six months.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2020

Historical avgQ1 2020

+0.7%

Avg return

Earnings day

+1.5%

Avg return

5 days after

-3.8%

Avg return

30 days after

50%

32 / 64 earnings

Positive

+24.8%

Q3 2017

Best reaction

-27.4%

Q2 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.0%-7.9%-32.6%
Q4 2025+4.0%+4.0%+10.1%
Q3 2025+1.9%+4.6%+3.2%
Q1 2025-4.1%+16.1%+8.1%
Q4 2024-0.6%+7.3%-24.4%
Q3 2024+0.7%-5.8%-26.6%
Q2 2024-5.9%-2.5%-5.1%
Q1 2024+7.3%+7.9%-23.2%
Q4 2023+13.3%+16.7%+33.3%
Q3 2023-5.6%-15.1%-3.8%
Q2 2023-10.8%-8.8%-42.2%
Q1 2023-2.6%-5.2%-22.1%
Q4 2022+8.6%+12.9%-54.0%
Q3 2022+3.6%+4.1%-16.2%
Q2 2022+9.2%+5.4%-10.3%
Q1 2022-6.7%-17.0%-22.1%
Q4 2021+10.0%+5.2%-44.2%
Q3 2021-21.0%-18.8%-36.4%
Q2 2021+1.0%-4.0%+1.6%
Q1 2021+7.6%+3.3%-8.3%
Q4 2020-0.4%+4.3%-12.2%
Q3 2020+2.7%-0.8%+2.5%
Q2 2020+0.5%-6.2%-13.0%
Q1 2020+6.3%+11.3%+14.0%
Q4 2019-2.8%-9.2%-19.5%
Q3 2019+0.9%+13.2%+10.3%
Q2 2019-27.4%-34.5%-40.9%
Q1 2019+10.5%+1.7%+2.9%
Q4 2018-7.1%-6.4%-18.1%
Q3 2018-2.1%+2.5%+2.5%
Q2 2018+8.7%+8.6%+19.0%
Q1 2018+2.1%+7.2%-30.4%
Q4 2017+18.8%+13.3%+22.8%
Q3 2017+24.8%+33.9%+125.8%
Q2 2017-7.8%-9.8%+11.0%
Q1 2017+5.8%+9.9%+4.1%
Q4 2016+13.1%+9.9%+79.4%
Q3 2016-1.1%+5.1%-0.6%
Q2 2016+1.6%+0.5%+7.4%
Q1 2016-12.3%
Q4 2015-0.2%
Q3 2015+4.3%
Q2 2015-5.6%
Q1 2015+13.3%
Q4 2014-2.7%
Q3 2014-1.8%
Q2 2014+7.4%
Q1 2014-2.9%
Q4 2013-2.5%
Q3 2013+15.8%
Q2 2013+11.9%
Q1 2013-4.1%
Q4 2012+1.6%
Q3 2012-14.1%
Q2 2012+0.6%
Q1 2012-1.0%
Q4 2011+9.5%
Q3 2011-1.5%
Q2 2011-5.4%
Q1 2011+3.6%
Q4 2010-4.9%
Q3 2010-4.8%
Q2 2010-2.2%
Q1 2010-10.8%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro